

Ephedrine Sulfate Injection, USP

ISSUED 10/25/99

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION
-----MATERIAL NAME: Ephedrine Sulfate Injection, USP
List Number: 3073MANUFACTURER: Hospital Products Division
Abbott Laboratories
Abbott Park, Illinois 60064EMERGENCY TELEPHONE NUMBER: 1-847-937-7970
CHEMTREC TELEPHONE NUMBER: 1-800-424-93002. COMPOSITION/INFORMATION ON INGREDIENTS
-----INGREDIENT NAME: Ephedrine Sulfate *
CAS/RTECS NUMBERS: 134-72-5/KB2625000
OSHA-PEL 8HR TWA: N/L
STEL: N/L
CEILING: N/L
ACGIH-TLV 8HR TWA: N/L
STEL: N/L
CEILING: N/L
OTHER 8HR TWA: 0.1 mg/m³, (Abbott Laboratories)
LIMITS STEL: N/A
CEILING: N/A

* Hazardous per OSHA criteria

3. HAZARDS INFORMATION

EMERGENCY OVERVIEW: In clinical use, the material is used as a bronchodilator and to treat shock. The active material stimulates the sympathetic nervous system. It is toxic by ingestion, and can exert changes on the heart, lungs, cardiovascular system and central nervous system.

ROUTE(S) OF ENTRY: Skin: Unlikely
Inhalation: Unlikely
Ingestion: Unlikely

Ephedrine Sulfate Injection, USP

ISSUED 10/25/99

3. HAZARDS INFORMATION, continued

INGESTION RATING: Possibly toxic

SKIN ABSORPTION RATING: N/D

INHALATION RATING: N/D

CORROSIVENESS RATING: N/D

SKIN CONTACT RATING: N/D

SKIN SENSITIZATION RATING: N/D

EYE CONTACT RATING: N/D

TARGET ORGANS: Sympathetic nervous system, respiratory system, central nervous system, heart, cardiovascular system

CARCINOGENICITY RATING: NTP: N/L IARC: N/L OSHA: N/L

ACGIH: N/L

None

SIGNS AND SYMPTOMS: N/D. In clinical use, adverse reactions include excitation, tremulousness, insomnia, nervousness, palpitation, tachycardia, restlessness, anxiety, dizziness, confusion, pallor, vertigo, precordial pain, arrhythmias, vertigo, dryness of the nose and throat, headache, sweating and urinary retention. Overdosage can produce nausea, vomiting, chills, cyanosis, fever, dilated pupils, blurred vision, opisthotonus, spasms, convulsions, respiratory distress and coma.

MEDICAL CONDITIONS AGGRAVATED BY EXPOSURE: N/D. Data suggest pre-existing cardiovascular, kidney, nervous system or ocular ailments.

Ephedrine Sulfate Injection, USP

ISSUED 10/25/99

4. FIRST AID MEASURES

EYES: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care, monitoring cardiovascular and respiratory function, as necessary.

SKIN: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care, monitoring cardiovascular and respiratory function, as necessary.

INGESTION: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care, monitoring cardiovascular and respiratory function, as necessary.

INHALATION: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care, monitoring cardiovascular and respiratory function, as necessary.

5. FIRE FIGHTING PROCEDURES

FLASH POINT: Non-flammable

FLASH POINT METHOD: N/A

LOWER EXPLOSIVE LIMIT(%): N/D

UPPER EXPLOSIVE LIMIT(%): N/D

AUTOIGNITION TEMPERATURE: N/D

FIRE & EXPLOSION HAZARDS: None

EXTINGUISHING MEDIA: Use media appropriate for primary cause of fire.

FIRE FIGHTING INSTRUCTIONS: Wear protective clothing and self-contained breathing apparatus.

Ephedrine Sulfate Injection, USP

ISSUED 10/25/99

6. ACCIDENTAL RELEASE MEASURES

SPILL OR RELEASE PROCEDURES: Absorb with suitable material, and containerize prior to disposal in accordance to Section 13. Use personal protective equipment recommended in Section 8.

7. HANDLING AND STORAGE

HANDLING: No special handling required.

STORAGE: Store at controlled room temperature of 15-30 degrees C (59-86 degrees F).

SPECIAL PRECAUTIONS: N/D

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

ENGINEERING CONTROLS: No special provisions are required under normal use conditions.

RESPIRATORY PROTECTION: Respiratory protection is not needed during normal product use.

SKIN PROTECTION: If skin contact is likely, impervious gloves are recommended.

EYE PROTECTION: Eye protection is not required during typical product use conditions. Eye protection is recommended if contact is likely.

OTHER PROTECTION: N/D

9. PHYSICAL AND CHEMICAL PROPERTIES

APPEARANCE/PHYSICAL STATE: Clear liquid

ODOR: N/A

BOILING POINT: Water (approx.)

MELTING/FREEZING POINT: Water (approx.)

VAPOR PRESSURE (mm Hg): N/A

Ephedrine Sulfate Injection, USP

ISSUED 10/25/99

9. PHYSICAL AND CHEMICAL PROPERTIES, continued

VAPOR DENSITY (Air=1): N/A
EVAPORATION RATE: N/A
BULK DENSITY: N/D
SPECIFIC GRAVITY: Water (approx.)
SOLUBILITY: Aqueous solution
pH: 4.5 - 7.0
VISCOSITY: Water (approx.)

10. STABILITY AND REACTIVITY

CHEMICAL STABILITY: Stable.

INCOMPATIBILITIES: Concentrated acids or bases.

HAZARDOUS DECOMPOSITION PRODUCTS: When heated to decomposition it emits very toxic fumes such as NO_x, SO_x and H₂SO₄.

HAZARDOUS POLYMERIZATION: N/D

11. TOXICOLOGICAL INFORMATION
-----ORAL TOXICITY: N/D. LD₅₀ equal to or greater than 75 to 1072 mg/kg in mice, rats and rabbits. Estimated oral MLD of 2000 mg in adults for ephedrine sulfate (Toxic).

DERMAL TOXICITY: N/D

INHALATION TOXICITY: N/D. Overdosage can occur from inhalation and mucous membrane application of ephedrine sulfate.

CORROSIVENESS: N/D

DERMAL IRRITATION: N/D

OCULAR IRRITATION: N/D. Ephedrine Sulfate produces dilated pupils (mydriasis) upon local application to the eyes.

DERMAL SENSITIZATION: N/D. Sensitization responses reported from application of a formulation containing 1% ephedrine in olive oil.

Ephedrine Sulfate Injection, USP

ISSUED 10/25/99

11. TOXICOLOGICAL INFORMATION, continued

SPECIAL TARGET ORGAN EFFECTS: N/D. In clinical use, ephedrine stimulates the sympathetic nervous system. It relaxes smooth muscle in the bronchi of the lungs, affects the heart, increases blood pressure and constricts some blood vessels while dilating others. Chronic nasal use can lead to chronic nasal congestion and personality changes in emotionally unstable people.

CARCINOGENICITY INFORMATION: N/D. Ephedrine sulfate was negative in NTP studies in rats and mice at diet concentrations up to 250 ppm.

12. ECOLOGICAL INFORMATION

ECOLOGICAL INFORMATION: N/D

13. DISPOSAL CONSIDERATIONS

WASTE DISPOSAL METHODS: Dispose of in accordance with local, state and federal regulations.

14. TRANSPORTATION INFORMATION

DOT STATUS: Not Regulated
PROPER SHIPPING NAME: N/A
HAZARD CLASS: N/A
UN NUMBER: N/A
PACKING GROUP: N/A
REPORTABLE QUANTITY: N/A

Ephedrine Sulfate Injection, USP

ISSUED 10/25/99

14. TRANSPORTATION INFORMATION, continued

IATA/ICAO STATUS: Not Regulated
PROPER SHIPPING NAME: N/A
HAZARD CLASS: N/A
UN NUMBER: N/A
PACKING GROUP: N/A
REPORTABLE QUANTITY: N/A

IMO STATUS: Not Regulated
PROPER SHIPPING NAME: N/A
HAZARD CLASS: N/A
UN NUMBER: N/A
PACKING GROUP: N/A
REPORTABLE QUANTITY: N/A
FLASH POINT: Non-flammable

15. REGULATORY INFORMATION

TSCA STATUS: N/A

CERCLA STATUS: N/L

SARA STATUS: N/L

RCRA STATUS: N/L

PROP 65 (CA): N/L

Ephedrine Sulfate Injection, USP

ISSUED 10/25/99

16. OTHER INFORMATION

LEGEND: N/A = Not Applicable
N/D = Not Determined
N/L = Not Listed
L = Listed
C = Ceiling
S = Short-term
(R) = Registered Trademark of Abbott Laboratories
(TM) = Registered Trademark of Abbott Laboratories

The information and recommendations contained herein are based upon information believed to be reliable. However, Abbott Laboratories does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform with actual conditions of usage may be required. Abbott Laboratories assumes no responsibility for results obtained or for incidental or consequential damages arising from the use of these data. No freedom from infringement of any patent, copyright or trademark is to be inferred.

APPROVED BY: DLF